Get email notification for articles from Ido Efrati
Follow
May. 4, 2021 6:18 PM
Israel’s Institute for Biological Research is considering restarting its ongoing clinical trial from the beginning on the COVID-19 vaccine that it is developing. The step would be taken in the hope of developing a version that is effective with a single dose, Haaretz has learned. According to sources, it became apparent from the first and second phases of the clinical trials on the two-shot Israeli BriLife vaccine that it would be possible to forgo the second shot if patients were given a higher dose in a single injection.